Tümay İpekçi, Professor of Urology at Bahçeşehir University, shared a post on X:
“First-of-its-kind genomic test predicts benefit from hormone therapy added to radiation for recurrent prostate cancer – American Society for Radiation Oncology (ASTRO).”
More posts on OncoDaily.
